Capricor Therapeutics Inc (CAPR) - Total Assets
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) holds total assets worth $355.95 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Capricor Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
Capricor Therapeutics Inc - Total Assets Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Capricor Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Capricor Therapeutics Inc's total assets of $355.95 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.9% |
| Accounts Receivable | $59.17K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Capricor Therapeutics Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Capricor Therapeutics Inc's current assets represent 90.7% of total assets in 2025, an increase from 0.0% in 1999.
- Cash Position: Cash and equivalents constituted 80.9% of total assets in 2025, up from 0.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Capricor Therapeutics Inc Competitors by Total Assets
Key competitors of Capricor Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Capricor Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.01 | 7.77 | 11.16 |
| Quick Ratio | 9.01 | 7.77 | 11.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $287.10 Million | $142.36 Million | $38.13 Million |
Capricor Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Capricor Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.04 |
| Latest Market Cap to Assets Ratio | 4.99 |
| Asset Growth Rate (YoY) | 108.8% |
| Total Assets | $355.95 Million |
| Market Capitalization | $1.78 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Capricor Therapeutics Inc's assets at a significant premium (4.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Capricor Therapeutics Inc's assets grew by 108.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual total assets of Capricor Therapeutics Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $355.95 Million | +108.79% |
| 2024-12-31 | $170.48 Million | +190.26% |
| 2023-12-31 | $58.73 Million | +17.25% |
| 2022-12-31 | $50.09 Million | +21.21% |
| 2021-12-31 | $41.33 Million | +19.39% |
| 2020-12-31 | $34.62 Million | +211.50% |
| 2019-12-31 | $11.11 Million | +20.19% |
| 2018-12-31 | $9.25 Million | -43.18% |
| 2017-12-31 | $16.27 Million | -13.19% |
| 2016-12-31 | $18.75 Million | +16.66% |
| 2015-12-31 | $16.07 Million | +17.88% |
| 2014-12-31 | $13.63 Million | +146.16% |
| 2013-12-31 | $5.54 Million | +2.11% |
| 2012-12-31 | $5.42 Million | +295.26% |
| 2011-12-31 | $1.37 Million | -62.57% |
| 2010-12-31 | $3.67 Million | +1.28% |
| 2009-12-31 | $3.62 Million | -43.75% |
| 2008-12-31 | $6.44 Million | -62.34% |
| 2007-12-31 | $17.09 Million | +406788.76% |
| 2006-12-31 | $4.20K | +1394.66% |
| 2005-12-31 | $281.00 | -55.75% |
| 2004-12-31 | $635.00 | -41.15% |
| 2003-12-31 | $1.08K | +4216.00% |
| 2002-12-31 | $25.00 | -89.71% |
| 2001-12-31 | $243.00 | -98.30% |
| 2000-12-31 | $14.26K | +4939.22% |
| 1999-12-31 | $283.00 | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more